Everolimus as a single agent in refractory or relapsed Hodgkin's lymphoma: the Brazilian Named Patient Program Experience

BACKGROUND: Despite all the scientific progress that has been made on understanding the disease, prognosis for patients with relapsed and refractory Hodgkin's lymphoma remains poor and the treatment is palliative in the majority of the cases. Thus, the aim of this study was to present the resul...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Rev Bras Hematol Hemoter
Asıl Yazarlar: Rocha, Talita Máira Bueno da Silveira da, Fortier, Sergio Costa, Fischer, Thais Rodrigues da Cunha, Perini, Guilherme Fleury, Gaiolla, Rafael Dezen, Fogliatto, Laura, Delamain, Marcia Torresan, Costa, Andressa Fragoso da, Castro, Nelson Siqueira de, Barretos, Wolney Gois, Souza, Cármino Antonio de, Buccheri, Valéria, Chiattone, Carlos Sérgio
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Sociedade Brasileira de Hematologia e Hemoterapia 2017
Konular:
Original Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5567422/
https://ncbi.nlm.nih.gov/pubmed/28830600
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bjhh.2017.03.008
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller